标题
Lactate dehydrogenase: a marker of diminished antitumor immunity
作者
关键词
-
出版物
OncoImmunology
Volume 9, Issue 1, Pages 1731942
出版商
Informa UK Limited
发表日期
2020-02-26
DOI
10.1080/2162402x.2020.1731942
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies
- (2019) Maria Cona et al. Cancers
- Clinicopathological characteristics associated with necrosis in pulmonary metastases from colorectal cancer
- (2019) Jun Suzuki et al. VIRCHOWS ARCHIV
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer
- (2019) Lisa König et al. BMC CANCER
- Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer
- (2019) MASAHIRO KATSURADA et al. ANTICANCER RESEARCH
- A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx).
- (2019) Jianjun Gao et al. JOURNAL OF CLINICAL ONCOLOGY
- Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
- (2019) Ming Yi et al. Molecular Cancer
- Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial
- (2019) Xinan Sheng et al. JOURNAL OF CLINICAL ONCOLOGY
- S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
- (2018) Nikolaus B Wagner et al. BRITISH JOURNAL OF CANCER
- Targeting tumor-associated acidity in cancer immunotherapy
- (2018) Ruben Lacroix et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy
- (2018) Tina Cascone et al. Cell Metabolism
- Targeting cancer metabolism to develop human lactate dehydrogenase ( h LDH)5 inhibitors
- (2018) Shao-Lin Zhang et al. DRUG DISCOVERY TODAY
- Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
- (2018) James Larkin et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer
- (2018) Laura Mezquita et al. JAMA Oncology
- LBA2Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients
- (2018) K Homicsko et al. ANNALS OF ONCOLOGY
- Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
- (2018) Richard W. Joseph et al. CLINICAL CANCER RESEARCH
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Increased CD3+ T cells with a low FOXP3+/CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients
- (2018) Hyojin Kim et al. MODERN PATHOLOGY
- Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative 18F-FDG PET/CT analysis
- (2018) Ellen C. de Heer et al. EJNMMI Research
- Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors
- (2018) Fausto Petrelli et al. MELANOMA RESEARCH
- Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials
- (2017) Dirk Schadendorf et al. EUROPEAN JOURNAL OF CANCER
- Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)
- (2017) Frédéric Bigot et al. EUROPEAN JOURNAL OF CANCER
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- Tumor LDH-A expression and serum LDH status are two metabolic predictors for triple negative breast cancer brain metastasis
- (2017) Tieying Dong et al. Scientific Reports
- Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma
- (2016) S Diem et al. BRITISH JOURNAL OF CANCER
- In Vivo Imaging of Tumor Metabolism and Acidosis by Combining PET and MRI-CEST pH Imaging
- (2016) Dario L. Longo et al. CANCER RESEARCH
- LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells
- (2016) Almut Brand et al. Cell Metabolism
- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
- (2016) A. Martens et al. CLINICAL CANCER RESEARCH
- Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells
- (2016) Naoki Horikawa et al. CLINICAL CANCER RESEARCH
- A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer
- (2016) Stephen M Hatfield et al. CURRENT OPINION IN PHARMACOLOGY
- Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy
- (2016) Laurent Dercle et al. EUROPEAN JOURNAL OF CANCER
- Angiogenesis inhibitors as therapeutic agents in cancer: Challenges and future directions
- (2016) Zhexuan Lin et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials
- (2016) Georgina V Long et al. LANCET ONCOLOGY
- Metabolic rewiring in melanoma
- (2016) B I Ratnikov et al. ONCOGENE
- The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy
- (2016) Luca Faloppi et al. Scientific Reports
- Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab
- (2016) J. Weber et al. Cancer Immunology Research
- Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma
- (2016) Asim Amin et al. Journal for ImmunoTherapy of Cancer
- Prognostic role of lactate dehydrogenase in solid tumors: A systematic review and meta-analysis of 76 studies
- (2015) Fausto Petrelli et al. ACTA ONCOLOGICA
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
- (2015) Chih-Hao Chang et al. CELL
- 3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067)
- (2015) J. Larkin et al. EUROPEAN JOURNAL OF CANCER
- Unknown
- (2015) EUROPEAN JOURNAL OF IMMUNOLOGY
- Proton pump inhibitors affect the gut microbiome
- (2015) Floris Imhann et al. GUT
- CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder
- (2015) Bo Wang et al. JOURNAL OF UROLOGY
- Immune Response Regulation in the Tumor Microenvironment by Hypoxia
- (2015) Sara Labiano et al. SEMINARS IN ONCOLOGY
- Unknown
- (2015) Oncotarget
- Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
- (2014) Ester Simeone et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Functional polarization of tumour-associated macrophages by tumour-derived lactic acid
- (2014) Oscar R. Colegio et al. NATURE
- Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer
- (2014) Chenxi Yin et al. OncoTargets and Therapy
- Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis
- (2014) T. J. Parmenter et al. Cancer Discovery
- Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab
- (2014) J. Yuan et al. Cancer Immunology Research
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- Tumor Hypoxia Does Not Drive Differentiation of Tumor-Associated Macrophages but Rather Fine-Tunes the M2-like Macrophage Population
- (2013) D. Laoui et al. CANCER RESEARCH
- Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis
- (2013) Chih-Hao Chang et al. CELL
- Relationships between LDH-A, Lactate, and Metastases in 4T1 Breast Tumors
- (2013) A. Rizwan et al. CLINICAL CANCER RESEARCH
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
- (2013) Gabriela Bindea et al. IMMUNITY
- Necrosis Degree Displayed in Computed Tomography Images Correlated With Hypoxia and Angiogenesis in Breast Cancer
- (2013) Xiuhong Shan et al. JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY
- Tumor-Derived Lactate Modifies Antitumor Immune Response: Effect on Myeloid-Derived Suppressor Cells and NK Cells
- (2013) Z. Husain et al. JOURNAL OF IMMUNOLOGY
- Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigen
- (2013) Andrew L Doedens et al. NATURE IMMUNOLOGY
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- New Aspects of an Old Drug – Diclofenac Targets MYC and Glucose Metabolism in Tumor Cells
- (2013) Eva Gottfried et al. PLoS One
- Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial
- (2013) Amanda Eustace et al. RADIOTHERAPY AND ONCOLOGY
- Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
- (2012) M Scartozzi et al. BRITISH JOURNAL OF CANCER
- Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-Infiltrating T Lymphocytes
- (2012) A. Calcinotto et al. CANCER RESEARCH
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
- (2012) Y. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa
- (2012) E. T. Clambey et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Metabolic Imaging: A Link between Lactate Dehydrogenase A, Lactate, and Tumor Phenotype
- (2011) I. Serganova et al. CLINICAL CANCER RESEARCH
- Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic Therapy
- (2011) M. I. Koukourakis et al. CLINICAL CANCER RESEARCH
- Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
- (2011) Andrea Facciabene et al. NATURE
- Lactate-Dehydrogenase 5 is overexpressed in non-small cell lung cancer and correlates with the expression of the transketolase-like protein 1
- (2010) Gian Kayser et al. Diagnostic Pathology
- HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment
- (2010) Cesar A. Corzo et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes
- (2010) A. J. Levine et al. SCIENCE
- LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)
- (2009) Sanjiv S. Agarwala et al. EUROPEAN JOURNAL OF CANCER
- Tumor necrosis is associated with increased alphavbeta3integrin expression and poor prognosis in nodular cutaneous melanomas
- (2008) Ingeborg M Bachmann et al. BMC CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started